Turner’s syndrome has been used as a model of primary hypogonadism to assess the role of estrogen-progestogen replacement therapy on scrum thymidine activity (TA) and somatomcdin-C (Sm-C) levels. 33 subjects with gonadal dysgenesis were studied: 10 untreated and 13 treated with estrogen-progestogen combination. In 10 untreated patients serum TA was 1.02 ± (SEM) 0.04 U/ml and serum Sm-C value was 27.82 ±4.14 nmol/1. both similar to those in the age-matched normal children. A positive correlation was found between Sm-C and the bone age (r = 0.891. ρ <0.002). In the i3 treated subjects, the estrogen-progestogen combination as replacement therapy induced a significant increase in Sm-C level (40.52 ± 4.30 nmol/1, ρ <0.05). No variation was observed for serum thymidine activity between the two groups of subjects.
- Estrogen replacement therapy
- Thymidine activity
- Tumor’s syndrome
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Pediatrics, Perinatology, and Child Health